A molecular inhibitor against pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive condition characterised by pathological inflammation and scarring in the lungs. The causes of IPF are unknown, and there is no cure, with most patients surviving approximately three years after diagnosis. Scientists of the EU-funded DOIIF project had previously developed an inhibitor of the OGG1 enzyme, which is implicated in DNA repair during oxidative stress. Since inhibition of OGG1 seems to reduce inflammation and fibrosis and slow down IPF, researchers aim to take a lead compound through preclinical development and clinical phase 1/2a for further commercialisation.
Fields of science
Call for proposal
See other projects for this call